Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 8 Neoplasm Metastasis 8 Carcinoma, Non-Small-Cell Lung 8 Breast Neoplasms 8 Colorectal Neoplasms 7 Prostatic Neoplasms 6 Urinary Bladder Neoplasms 5 Leukemia, Myeloid, Acute 5 Squamous Cell Carcinoma of Head and Neck 4 Ovarian Neoplasms 4 Lung Neoplasms 4 Glioblastoma 4 Triple Negative Breast Neoplasms 3 Mouth Neoplasms 3 Head and Neck Neoplasms 3 Carcinoma, Transitional Cell 3 Carcinoma, Ovarian Epithelial 3 Uterine Cervical Neoplasms 2 Ureteral Neoplasms 2 Stomatitis 2 Recurrence 2 Oropharyngeal Neoplasms 2 Melanoma 2 Laryngeal Neoplasms 2 Gastrointestinal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma 2 COVID-19 2 Brain Neoplasms 2 Adenocarcinoma 2

Interventions

Levetiracetam 2 Temozolomide 1 Standard of Care 1 Pregabalin 1 Medical Marijuana 1 Drug Therapy 1 Aspirin 1 Anticonvulsants 1 Anastrozole 1 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Seizures × Standard of Care × Clear all

NCT04450160 2020-06-29

AEO

MetVital, Inc.

Phase 2 Unknown

Glioblastoma, Seizures

Data powered by HemOnc (CC BY 4.0) Colophon ⚡